VALUATION HIGHLIGHTS

1. Intuitive Surgical Products constitute 81% of the Trefis price estimate for Intuitive Surgical's stock.
2. Intuitive Surgical Services constitute 15% of the Trefis price estimate for Intuitive Surgical's stock.

WHAT HAS CHANGED?

Latest Earnings: Q4 and Full Year 2025

Intuitive Surgical reported Q4 2025 revenue of $2.87 billion, an 18.8% increase year-over-year, exceeding consensus estimates. Non-GAAP EPS for the quarter was $2.53, up 14.5% compared to $2.21 in the prior year. For the full year 2025, revenue reached $10.07 billion, up 21% from 2024. The strong performance was driven by an 18% growth in worldwide da Vinci procedure volume and a significant 51% surge in Ion procedure volume. The company placed 532 da Vinci systems in Q4, with the new da Vinci 5 platform accounting for 303 of those placements as adoption accelerates.

Note: Intuitive Surgical's FY'25 ended on Dec. 31, 2025.

Full Launch of da Vinci 5 Platform

Following a limited rollout, Intuitive Surgical transitioned to the full commercial launch of its next-generation da Vinci 5 system in late 2025. The platform, which features 10,000 times more computing power and integrated Force Feedback technology, received expanded FDA clearance for cardiac procedures including mitral valve repair. This regulatory milestone and the subsequent wide release are expected to drive a multi-year system replacement cycle across major hospital networks in the U.S. and Europe, where CE Mark was also recently secured.

POTENTIAL UPSIDE & DOWNSIDE TO TREFIS PRICE

Below are key drivers of Intuitive Surgical's value that present opportunities for upside or downside to the current Trefis price estimate:

Instruments and Accessories

• Procedure Volume Outperformance: Instruments and Accessories revenue, which accounts for approximately 60% of total sales, grew 18.5% to $6.02 billion in 2025. Management's 2026 procedure growth guidance of 13-15% is viewed as conservative; if adoption of general surgery procedures in international markets continues at its current 23% clip, there is significant upside to recurring revenue estimates.


• Ion Platform Scaling: The Ion endoluminal system for lung biopsy saw procedure growth of 51% in 2025. As the installed base reached 995 systems, the pull-through of high-margin consumables is reaching a critical mass. Continued clinical validation for earlier stage lung cancer detection presents a major growth lever that may be under-modeled in long-term segment projections.

For additional details, select a division from the interactive Trefis split for Intuitive Surgical at the top of the page.

BUSINESS SUMMARY

Intuitive Surgical is the global pioneer in robotic-assisted minimally invasive surgery. Its business model is centered on a "razor-and-blade" strategy, where the initial placement of da Vinci and Ion surgical systems generates high-margin, recurring revenue through the sale of proprietary instruments, accessories, and multi-year service contracts. Currently, approximately 75% of the company's total revenue is recurring, providing a stable financial foundation while it expands into new therapeutic areas like endoluminal diagnostics and digital surgery ecosystems.

SOURCES OF VALUE

The recurring revenue generated by the Instruments and Accessories segment is the primary engine of Intuitive's valuation.

Unrivaled Installed Base and Ecosystem

With over 11,100 da Vinci systems installed globally, Intuitive has built a massive competitive moat. This installed base is supported by an ecosystem of over 20 million historical procedures, providing the data necessary to refine its AI-driven surgical insights and making it difficult for competitors to displace the existing infrastructure and surgeon training protocols.

Operating Margin Resilience

Intuitive maintains pro forma operating margins around 37% despite significant R&D investment. This profitability is protected by the high switching costs associated with its proprietary instruments and the technical complexity of its multi-port and single-port platforms, which command premium pricing in the medical technology sector.

KEY TRENDS

Next-Generation Computing in Surgery

The industry is shifting from mechanical robotics to data-driven surgery. The da Vinci 5 platform’s integration of real-time "Force Gauge" data and intraoperative video replay allows for precision that was previously unattainable. This trend toward "digital laparoscopy" positions Intuitive as a software leader in addition to its hardware dominance.

Expansion into Non-Surgical Diagnostics

Through its Ion platform, Intuitive is moving "upstream" in the patient care pathway. By focusing on robotic-assisted biopsy for lung cancer, the company is tapping into the diagnostic market, which offers a different growth trajectory and less exposure to the elective surgery cycles that traditionally impact the MedTech sector.

Globalization of Robotic Surgery

Growth is increasingly shifting to international markets, particularly Japan and South Korea, where procedure volumes grew by double digits in 2025. As reimbursement environments improve for robotic-assisted surgery outside the U.S., these regions are becoming primary contributors to system placement growth.